By Ryan Vlastelica
NEW YORK (Reuters) - U.S. stocks were slightly lower on Friday, with investors finding few reasons to extend a long-running rally, even as the latest economic data joined the trend of better-than-expected reports on the economy.
A note of caution entered the market as Britain raised its international terrorism threat level to the second highest level in response to possible attacks being planned in Syria and Iraq. Still, major U.S. indexes remained on track for their fourth straight week of gains.
Stocks have been strong of late, with investors taking any opportunity to buy on dips. However, this week's trading volume has been among the lightest of the year, with action especially muted on Friday, ahead of the Labor Day holiday in the United States for which markets will be closed on Monday.
"Typically after the market goes up this much this quickly, you'd expect some kind of pullback, but we've become conditioned to buy on dips. That's almost ingrained in the market," said Quincy Krosby, market strategist at Prudential Financial in Newark, New Jersey.
The Britain threat level "doesn't sound good, but unless there's definite news that's worse than things we've already seen recently, the market should be able to process it and move on," Krosby said.
In the latest economic data, the pace of business activity in the U.S. Midwest rebounded more than expected in August, signaling a pickup in that region's economy. Separately, U.S. consumer sentiment rose more than expected, according to the final August reading from the Thomson Reuters/University of Michigan Surveys of Consumers.
The Dow Jones industrial average fell 40.05 points or 0.23 percent, to 17,039.52, the S&P 500 lost 2.03 points or 0.1 percent, to 1,994.71 and the Nasdaq Composite dropped 3.75 points or 0.08 percent, to 4,553.95.
For the week, the Dow is up 0.2 percent, the S&P is up 0.3 percent and the Nasdaq is up 0.4 percent, the fourth straight week of gains for all three. For the month of August, the Dow is up 2.9 percent, S&P is up 3.3 percent and the Nasdaq is up 4.3 percent. Both the Dow and S&P have climbed in six of the past seven months.
U.S. shares of AstraZeneca rose 1.9 percent to $75.68 on news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.
Splunk Inc jumped 15 percent to $51.89 a day after posting strong revenue growth and raising its full-year sales outlook.
(Editing by Chizu Nomiyama and Meredith Mazzilli)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
